Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +10.5%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.1%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (537)

clinicaltrialsPublishedShowing 751–800 of 973 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07114432	RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma	not yet recruiting	Phase 1	19	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Aug 11, 2025	clinicaltrials
NCT03314636	Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET)	active not recruiting	Phase 2	53	Oslo University HospitalOTHER	3	Aug 8, 2025